# Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years

> **NCT00783653** · PHASE1,PHASE2 · COMPLETED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 22 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00783653
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2013-07
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783653, "Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00783653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*